Malvern gene therapy company targeting heart diseases raises $17M
XyloCor Therapeutics, a Malvern gene therapy company developing new cardiovascular disease treatments, has closed a $17 million series A financing.
The equity financing deal was co-led by Sofinnova Ventures in Menlo Park, Calif., and Life Sciences Partners (LSP), which is based in The Netherlands and has a office in Waltham, Mass.
Proceeds from the financing will be used by XyloCor to advance the development of its lead product candidate, XC001, and to "expand the companies business and operational…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: John George Source Type: news
More News: Biotechnology | Cardiology | Cardiovascular | Gene Therapy | Genetics | Health Management | Heart | Men | Netherlands Health